Stockscreener 앱 받기
1.76
1.15%
0.02
시간 외 거래:
1.76
전일 마감가:
$1.74
열려 있는:
$1.75
하루 거래량:
3.07M
Relative Volume:
1.29
시가총액:
$400.05M
수익:
-
순이익/손실:
$-179.82M
주가수익비율:
-1.3233
EPS:
-1.33
순현금흐름:
$-159.16M
1주 성능:
-12.00%
1개월 성능:
+38.58%
6개월 성능:
+66.04%
1년 성능:
+115.42%
1일 변동 폭
$1.665
$1.7897
1주일 범위
$1.665
$2.23
52주 변동 폭
$0.6617
$2.23
Gossamer Bio Inc Stock (GOSS) Company Profile
명칭
Gossamer Bio Inc
전화
(858) 684-1300
주소
3115 MERRYFIELD ROW, SAN DIEGO, CA
GOSS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
1.76 | 450.06M | 0 | -179.82M | -159.16M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-14 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-04-05 | 재개 | Wedbush | Outperform |
| 2023-07-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-03-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-03-01 | 개시 | Guggenheim | Neutral |
| 2022-12-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-12-07 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-12-07 | 다운그레이드 | SMBC Nikko | Outperform → Neutral |
| 2022-10-20 | 개시 | Goldman | Buy |
| 2022-09-21 | 개시 | JP Morgan | Neutral |
| 2022-09-19 | 개시 | Wedbush | Outperform |
| 2022-04-18 | 개시 | Raymond James | Outperform |
| 2022-04-06 | 개시 | UBS | Buy |
| 2022-01-10 | 업그레이드 | SMBC Nikko | Neutral → Outperform |
| 2021-11-09 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-09-21 | 재개 | Piper Sandler | Overweight |
| 2020-06-29 | 개시 | H.C. Wainwright | Buy |
| 2020-04-22 | 개시 | Piper Sandler | Overweight |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2019-12-03 | 재개 | BofA/Merrill | Buy |
| 2019-10-30 | 개시 | Berenberg | Buy |
| 2019-03-05 | 개시 | Barclays | Overweight |
| 2019-03-05 | 개시 | BofA/Merrill | Buy |
| 2019-03-05 | 개시 | Evercore ISI | Outperform |
| 2019-03-05 | 개시 | SVB Leerink | Outperform |
모두보기
Gossamer Bio Inc 주식(GOSS)의 최신 뉴스
Institutional investors in Gossamer Bio, Inc. (NASDAQ:GOSS) see US$54m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance
H.C. Wainwright Maintains Gossamer Bio(GOSS.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)August 7, 2025 - BioSpace
Gossamer Bio earnings beat by $0.01, revenue topped estimates - Investing.com Australia
Gossamer Bio Reports Q2 2025 Financials, Announces PROSERA Phase 3 Topline Results Expected in February 2026, and First Site Activations for Registrational Phase 3 SERANATA Study in PH-ILD Expected in Q4 2025. - AInvest
Gossamer Bio 2025 Q2 Earnings Sharp Net Loss Amid Revenue Drop - AInvest
Gossamer Bio 2025 Q2 Earnings Sharp Net Income Decline of 177.7% - AInvest
Gossamer Bio shares fall 7.41% premarket despite beating earnings expectations. - AInvest
Gossamer Bio Inc. Exceeds Q2 Expectations Despite LossNews and Statistics - IndexBox
Gossamer Bio: Q2 Earnings Snapshot - New Haven Register
Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update - BioSpace
Gossamer Bio shares rise 1.39% after-hours despite Q2 revenue drop of 88%. - AInvest
Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
GOSS Achieves Strong Q2 Revenue and Prepares for Commercial Expa - GuruFocus
Gossamer Bio Reports Q2 Revenue Drop of 88% - AInvest
Gossamer Bio Q2 revenue drops 88% - MarketScreener
Gossamer Bio's 390-Patient PAH Trial Nears Crucial February Readout, $213M Cash Runway - Stock Titan
Will Gossamer Bio Inc. price bounce be sustainableFree Smart Trade Plans With Risk Protection - Newser
Real time scanner hits for Gossamer Bio Inc. explainedWeekly Gain Forecast with Momentum Indicators - Newser
How Gossamer Bio Inc. stock performs during market volatilityRSI and MACD Signal Summary with Trends - Newser
Can Gossamer Bio Inc. rally from current levelsStrategy Builder for Growth Focused Traders - Newser
Why is Gossamer Bio Inc. stock attracting strong analyst attentionExponentially increasing returns - Jammu Links News
Custom strategy builders for tracking Gossamer Bio Inc.Market Liquidity and Price Flow Analysis - Newser
Published on: 2025-08-04 06:30:01 - beatles.ru
Is Gossamer Bio Inc. forming a reversal patternReal-Time Investment Signal Forecast with AI - Newser
How volatile is Gossamer Bio Inc. stock compared to the marketCapitalize on market momentum for maximum gains - Jammu Links News
Why Gossamer Bio Inc. is moving todayStock Market Watch with Smart Filters - Newser
Why Gossamer Bio Inc. stock attracts strong analyst attentionLong-Term Allocation Strategy Summary Breakdown - Newser
What are the latest earnings results for Gossamer Bio Inc.Capitalize on fast-moving stock trends - Jammu Links News
What is the dividend policy of Gossamer Bio Inc. stockCapitalize on high-yield stocks early - Jammu Links News
When is Gossamer Bio Inc. stock expected to show significant growthFree Expert Stock Watchlist - Jammu Links News
How strong is Gossamer Bio Inc. company’s balance sheetUnlock daily trading alerts for profits - Jammu Links News
Is it the right time to buy Gossamer Bio Inc. stockCapitalize on stocks with high profit margins - Jammu Links News
How does Gossamer Bio Inc. compare to its industry peersInvest smarter with real-time trading alerts - Jammu Links News
Does Gossamer Bio Inc. stock perform well during market downturnsAchieve breakthrough profits with smart strategies - Jammu Links News
Is Gossamer Bio Inc. stock poised for growthFree Fast Gaining Stock Screener Report - Newser
Gossamer Bio Inc. Stock Analysis and ForecastAmplify your gains with low-risk picks - Jammu Links News
What institutional investors are buying Gossamer Bio Inc. stockBuild a portfolio that stands the test of time - Jammu Links News
How many analysts rate Gossamer Bio Inc. as a “Buy”Discover market opportunities others miss - Jammu Links News
What catalysts could drive Gossamer Bio Inc. stock higher in 2025Double-digit growth - Jammu Links News
What are analysts’ price targets for Gossamer Bio Inc. in the next 12 monthsFree Stock Selection - Jammu Links News
Regression analysis insights on Gossamer Bio Inc. performanceFree Trade Ready Stock Watch for Short Term - Newser
Is this a good reentry point in Gossamer Bio Inc.Smart Entry Signals for Active Traders - Newser
Institutional scanner results for Gossamer Bio Inc.Free Smart Trade Plans With Risk Protection - Newser
Institutional Investors Have a Lot Riding on Gossamer Bio, Inc. (NASDAQ:GOSS) With 63% Ownership - 富途牛牛
Gossamer Bio Inc (GOSS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):